Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
759 studies found for:    Open Studies | "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Recruiting Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immune System Diseases
Interventions: Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Procedure: Allogeneic hematopoietic stem cell transplantation
2 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
3 Recruiting Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
4 Recruiting Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)
Condition: Chronic Granulomatous Disease
Intervention: Drug: Busulfan
5 Recruiting Temozolomide Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Condition: Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Intervention: Drug: temozolomide combined with endostatin
6 Recruiting Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Conditions: Lymphoma;   Chronic Lymphocytic Leukemia;   Non-Hodgkin Lymphoma;   T-cell Lymphoma
Interventions: Drug: IPI-145;   Drug: Rituximab;   Drug: Bendamustine
7 Unknown  Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
8 Recruiting Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
Conditions: Malignant Solid Tumor;   Childhood Solid Tumor
Intervention: Drug: Sirolimus, Cyclophosphamide, Topotecan
9 Not yet recruiting Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Chlorambucil;   Drug: Obinutuzumab
10 Recruiting the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient
Condition: Acute Myeloid Leukemia
Intervention: Drug: Cyclosporin A,mycophenolate mofetil,Methotrexate
11 Recruiting SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
Condition: Sickle Cell Disease
Interventions: Procedure: Haploidentical Transplant;   Drug: Alemtuzumab;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Sirolimus
12 Recruiting Trabectedin First Line Therapy In Unfit Sarcoma Study
Conditions: Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive;   Standard Chemotherapy
Intervention: Drug: Trabectedin
13 Not yet recruiting Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Stage III AIDS-related Lymphoma;   Stage IV AIDS-related Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: lomustine;   Drug: etoposide;   Drug: procarbazine hydrochloride;   Other: laboratory biomarker analysis
14 Recruiting Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: A: Fludarabine + Busulphan;   Drug: B: Fludarabine + Thiotepa
15 Recruiting Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia
Condition: Leukemia
Interventions: Drug: Fludarabine;   Drug: Clofarabine;   Drug: Busulfan;   Drug: SAHA;   Procedure: Stem Cell Infusion (SCT);   Drug: Thymoglobulin
16 Recruiting Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
Condition: Human Immunodeficiency Virus
Interventions: Drug: Busulfan;   Biological: Cal-1 modified HSPC;   Biological: Cal-1 modified CD4+ T lymphocytes
17 Recruiting Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: mibefradil dihydrochloride;   Drug: temozolomide;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Other: pharmacological study
18 Recruiting A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone (or equivalent)
19 Recruiting Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Rituximab, Bendamustine, Cytarabine.
20 Recruiting T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Condition: Metastatic Cancer That Express the MAGE-A3-DP4 Antigen
Interventions: Biological: Anti-MAGE-A3-DP4 TCR;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years